Gemeprost

Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.

Gemeprost
Clinical data
Trade namesCervagem
Other namesmethyl (E)-7-[(1R,2S,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]-5-oxo-cyclopentyl]hept-2-enoate
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
    Routes of
    administration
    Pessary
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    CompTox Dashboard (EPA)
    ECHA InfoCard100.058.869
    Chemical and physical data
    FormulaC23H38O5
    Molar mass394.552 g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Clinical use

    It is used as a treatment for obstetric bleeding.

    It is used with mifepristone to terminate pregnancy up to 24 weeks gestation.[1]

    Side effects

    Vaginal bleeding, cramps, nausea, vomiting, loose stools or diarrhea, headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mild pyrexia. Rare: Uterine rupture, severe hypotension, coronary spasms with subsequent myocardial infarctions.

    References

    1. Bartley J, Brown A, Elton R, Baird DT (October 2001). "Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation". Human reproduction (Oxford, England). 16 (10): 2098–102. doi:10.1093/humrep/16.10.2098. PMID 11574498. Retrieved 2008-10-29.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.